Drug intelligence / Profile preview

Remeson

Development stage
Unknown
Lead developer
Learmont Pharmaceuticals
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Remeson is a brand of methylprednisolone marketed by Learmont Pharmaceuticals, an Indian pharmaceutical distribution company. Methylprednisolone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties. It acts as an agonist of the glucocorticoid receptor; upon binding, the receptor-ligand complex translocates to the cell nucleus and modulates the transcription of genes involved in the inflammatory response. This mechanism leads to the inhibition of pro-inflammatory cytokines and the induction of anti-inflammatory proteins. Remeson is available in multiple strengths as part of a commercial generic series and is used to treat a wide range of conditions, including severe allergic reactions, asthma, rheumatoid arthritis, and systemic lupus erythematosus.

Brand names
RemesonRemeson-4Remeson4Remeson 4Remeson-8Remeson8Remeson 8Remeson-16Remeson16Remeson 16Remeson-24Remeson24Remeson 24Remeson-32Remeson32Remeson 32
Other names
methylprednisolone
02

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Remeson.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remeson.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call